MRIGlobal is a trusted partner in global health surveillance for infectious disease preparedness and response.
Deadly viruses like Ebola and COVID-19 have affected millions across the globe. MRIGlobal is a trusted partner to government and commercial customers, utilizing our high-containment biological laboratories to make scientific advancements and save lives around the world.
Developing diagnostic assays to expand and accelerate the delivery of high-quality clinical diagnostic tools
Evaluating the safety and efficacy of vaccines and therapeutics used in infectious disease response and control
Supporting human trial efforts to test infectious disease vaccine and treatment efforts
Building and managing studies for virus transmission to aid in future disease prevention and response efforts
Mobile Labs for Rapid, Localized Response Efforts
In addition to global health surveillance, we have engineered, deployed, and staffed mobile laboratories across the globe, supporting localized disease response efforts.
These units and our team always stand ready to assist countries and patients in need with point-of-care diagnostics.
MRIGlobal disease response scientists work in High-Containment Biosecurity Laboratories obtaining regulatory clearances for diagnostic devices and viral detection assays.
MRIGlobal scientists and virology experts develop, test, and evaluate methods for use with cutting-edge technologies to detect viral infections in humans, animals, and the environment. We develop methods and technologies for disease detection, response, and control, as well as global surveillance for disease prevention. Our work in disease response supports our mission of using science and technology to create solutions for a safer, healthier, more sustainable world.
Frequently Asked Questions About Disease Response Efforts
The order of operations is to detect the disease in people (or animals for some diseases) as early as possible.
If things get worse, countries may ask for assistance when resources are not available or limited, as in remote locations or in the case of new diseases, usually through the Africa Union, WHO, and other trusted partners.
MRIGlobal’s response to these requests for assistance may include:
The COVID-19 pandemic provided the opportunity for us to help accelerate disease response through advanced diagnostic tools. It enabled the rapid introduction of at-home testing with relatively easy “rapid” assays to help determine whether a person tested positive for SARS-CoV-2, the virus that causes COVID-19.
The pandemic also enabled telemedicine in a way that was slow to emerge previously. With tests in the hands of patients and then enabling their contact with a healthcare professional to help manage the disease case, healthcare improved worldwide, even in emerging countries with limited infrastructure.
Now, we are working on the future of at-home and field-forward diagnostic assays that can test for a variety of viruses, including COVID-19. This will have a profound impact on health management for people with other comorbidities like diabetes and autoimmune disorders.
Additionally, following our support for the response to the 2014-2016 Ebola outbreak, we developed our Athena mobile laboratories, which can be deployed around the world to support local and rapid response.
At the forefront of MRIGlobal’s disease response efforts is our mobile laboratories. In response to the Ebola outbreak, we engineered, deployed, and staffed labs outfitted with testing and diagnostic capabilities to aid in disease detection.
Building upon lessons learned, our team of engineers evolved mobile lab technology with our Athena Mobile Lab. Instead of using an ISO container as the basis of the design, our engineers created a fully customizable structure that greatly increases the laboratory’s capabilities. As a result, this lab improves work ergonomics, while still allowing for easy transport via trucks, boats, railcars, and airplanes.
We designed the Athena Mobile Lab to fill the need for a gold standard mobile model that allows diagnostic assays to be closer to a collection event. This allows researchers to promptly collect and assess the chemical, biological, biometric, or other evidence necessary to reach a diagnosis, decreasing the time between collection and test results.